RecruitingNCT07219953
Brenipatide for alcohol use and drinking risk
About this title
A Study of Brenipatide in Participants With Alcohol Use Disorder
Read the official source — NCT07219953Medication studyAges 18–75Multiple countriesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- Scottsdale and 115 more locationsSee all locations and recruitment
- Participation duration
- About 56 weeks
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 16, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 1,100
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, United Kingdom, Belgium, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07219953
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)
Recruitment & locations
RecruitingScottsdale, United States · Little Rock, United States · Los Angeles, United States
97 more locations
- Riverside, United States
- San Diego, United States
- San Francisco, United States
- Lakeland, United States
- Lauderhill, United States
- Maitland, United States
- Miami, United States
- Miami Gardens, United States
- Orlando, United States
- Tampa, United States
- Chicago, United States
- Baltimore, United States
- Rockville, United States
- Boston, United States
- Foxborough, United States
- The Bronx, United States
- Philadelphia, United States
- Providence, United States
- Sioux Falls, United States
- Dallas, United States
- DeSoto, United States
- Houston, United States
- Fairfax, United States
- Diepenbeek, Belgium
- Kluisbergen, Belgium
- Machelen, Belgium
- Mechelen, Belgium
- Oudenaarde, Belgium
- Beijing, China
- Changsha, China
- Cheng Du Shi, China
- Chengdu, China
- Guangzhou, China
- Hangzhou, China
- Harbin, China
- Hefei, China
- Huzhou, China
- Jinan, China
- Kunming, China
- Ningbo, China
- Shanghai, China
- Shenzhen, China
- Shijiazhuang, China
- Sichuan, China
- Wuhu, China
- Xi'an, China
- Xiamen, China
- Xianyang, China
- Xinxiang, China
- Zhenjiang, China
- Zhumadian, China
- Berlin, Germany
- Dresden, Germany
- Hamburg, Germany
- Mannheim, Germany
- Offenbach, Germany
- Schwerin, Germany
- Chūōku, Japan
- Fukuoka, Japan
- Karatsu, Japan
- Kobe, Japan
- Nagasaki, Japan
- Nakano, Japan
- Nishi, Japan
- Shibuya City, Japan
- Shinjuku, Japan
- Shinjuku-ku, Japan
- Tokyo, Japan
- Tsukuba, Japan
- Yokohama, Japan
- Yoshinogari-cho, Kanzaki-gun, Japan
- Anyang-si, South Korea
- Busan, South Korea
- Cheongju-si, South Korea
- Guri-si, South Korea
- Incheon, South Korea
- Junggu, South Korea
- Namdong-gu, South Korea
- Seogu, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Uijeongbu-si, South Korea
- Changhua County, Taiwan
- Hualien City, Taiwan
- Taichung, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Blackpool, United Kingdom
- Doncaster, United Kingdom
- Eastbourne, United Kingdom
- Glasgow, United Kingdom
- Hayle, United Kingdom
- Hounslow, United Kingdom
- London, United Kingdom
- Newquay, United Kingdom
- Preston, United Kingdom
- Rotherham, United Kingdom
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including LY3537031 and Placebo.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as recruiting.
